A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8742 in Hepatitis C Infected Males.
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Elbasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Oct 2013 Results will be presented at the 64th American Association for the Study of Liver Diseases Annual Meeting (AASLD) according to a Merck media release.
- 28 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.